Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00514995

Sodium Oxybate in the Treatment of Binge Eating Disorder

Sponsor: Jazz Pharmaceuticals

Updated 5 times since 2017 Last updated: Jun 21, 2011 Started: Aug 31, 2007 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Binge Eating Disorder and is currently completed. Jazz Pharmaceuticals leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jazz Pharmaceuticals
Lindner Center of HOPE
University of Cincinnati

Data source: Lindner Center of HOPE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mason, United States